Reuters logo
BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data
March 21, 2013 / 12:10 PM / 5 years ago

BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data

NEW YORK, March 21 (Reuters) - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below